{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003998","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.319821+00:00","generated_at":"2026-06-07T02:12:30.185256+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M","bullets":["Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.","Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.","SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.","EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003998","json":"https://secwatch.observer/filing/0001193125-24-003998.json","markdown":"https://secwatch.observer/filing/0001193125-24-003998.md","text":"https://secwatch.observer/filing/0001193125-24-003998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/d51181d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:12:30.185256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6465d59f447e9f1f2cb2333c96eaa13b41146041","claim":"Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.","evidence_excerpt":"Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI ® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6465d59f447e9f1f2cb2333c96eaa13b41146041","claim":"Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.","evidence_excerpt":"Approximately $114 million and $275 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6465d59f447e9f1f2cb2333c96eaa13b41146041","claim":"Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.","evidence_excerpt":"Approximately $24 million and $91 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}